Findings seen in as little as one month of treatment through 18 months of treatment<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Sept. 2, 2025 (HealthDay News) — Insomnia patients taking cannabis-based medicinal products report better quality sleep, according to a study published online Aug. 27 in PLOS Mental Health<\/em>.<\/p>\n Arushika Aggarwal, from Imperial College London, and colleagues assessed changes in sleep-specific and general patient-reported outcome measures in individuals prescribed cannabis-based medicinal products for insomnia, as well as the incidence of adverse events. The analysis included 124 patients with primary insomnia identified from the U.K. Medical Cannabis Registry.<\/p>\n The researchers found that Single-Item Sleep Quality Scale scores showed improvement from baseline (2.66) to one (5.67), three (5.41), six (4.80), 12 (4.24), and 18 months (3.81). Generalized Anxiety Disorder-7 scores improved at all time points from baseline to 18 months. For the EuroQol-5 Dimension-5 Level dimensions of usual activities, pain\/discomfort, anxiety\/depression, and index values, there were also significant improvements. Eleven people (8.87 percent) reported a total of 112 adverse events, but none were disabling or life-threatening.<\/p>\n “These findings support the potential role of medical cannabis as a medical option where conventional treatments have proven ineffective, though further randomized trials are needed to confirm long-term efficacy,” coauthor Simon Erridge, M.B.B.S., also from Imperial College London, said in a statement.<\/p>\n Several authors disclosed ties to Curaleaf Clinic, a licensed and regulated private clinic with specialist doctors who can prescribe medical cannabis to eligible patients.<\/p>\n